Clinical trials: Gene, p53
Colorectal Cancer, APC Gene Mutation
Patogenic Mutation in 5 Genes
This is a pathogenic mutation profile of colorectal patients specifically in 5 genes, i.e. APC, TP53, PIK3CA, KRAS, and MLH1. Single nucleotide variants identified were synchronized with patients' characteristics.
- Conditions
- Colorectal Cancer, APC Gene Mutation, TP53 Gene Mutation, PIK3CA Gene Mutation
- Trial name
- NCT04976439
- Testing
- co-occuring mutation
- Where
- Indonesia
- Volunteers
- 22 people
- Sponsor
- Dr Cipto Mangunkusumo General Hospital
Lung Cancer
Gene Therapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
RATIONALE: Inserting the gene for p53 into a person's cancer cells may improve the body's ability to fight cancer. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00004225
- Testing
- Ad5CMV-p53 gene, radiation therapy
- Where
- United States
- Sponsor
- Eastern Cooperative Oncology Group
Acute Myeloid Leukemia
Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia
This trial studies the side effects of nivolumab in combination with decitabine and venetoclax and to see how well they work in treating patients with TP53-mutated acute myeloid leukemia.
- Trial name
- NCT04277442
- Testing
- Decitabine, Nivolumab, Venetoclax
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Hepatocellular Carcinoma (HCC)
Trans-catheter Arterial Embolization Combined With p53 Gene Therapy for Treatment of Advanced Hepatocellular Carcinoma
An open-labeled, randomized, active-controlled phase II study to investigate clinical efficacy and immunoreaction using trans-catheter arterial embolization (TAE) combined with p53 gene therapy in treatment of advanced…
- Trial name
- NCT02509169
- Testing
- TAE plus P53 gene, TAE
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shenzhen SiBiono GeneTech Co.,Ltd
Colorectal Cancer Metastatic, Colorectal Cancer Stage IV
The p53 Colorectal Cancer Trial
Single center, open labeled, phase 2 clinical trial, where patients with metastatic colorectal cancer are selected for treatment with dose dense Cyclophosphamide every second week based on TP53 mutation status; i.e.
- Conditions
- Colorectal Cancer Metastatic, Colorectal Cancer Stage IV, TP53 Gene Mutation
- Trial name
- NCT03149679
- Testing
- Cyclophosphamide
- Where
- Norway
- Volunteers
- 12 people
- Sponsor
- Haukeland University Hospital
Advanced Malignant Thyroid Tumors
rAd-p53 Gene Therapy for Advanced Malignant Thyroid Tumors
This is multicenter, open-label, randomized, active-controled, phase IV study of local direct intra-tumor injection of rAd-p53 monotherapy, with concurrent radioactive iodine , or combination with surgery for treatment of…
- Trial name
- NCT00902122
- Testing
- rAd-p53 gene, surgery, p53 gene therapy
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Shenzhen SiBiono GeneTech Co.,Ltd
Lung Neoplasms, Gene, p53
Is There Any Relation Between Serum Anti-p53 Antibody and TLG, MTV and SUV as PET Parameters in Lung Cancer Patients?
p53 is a tumor suppressor gene which plays an important role in controlling normal cell proliferation regulation that is located on the chromosome 17 (17p13.1). It is the most common goal of genetic alteration in many tumors.
- Trial name
- NCT02309567
- Testing
- Blood Collection
- Where
- Turkey (Türkiye)
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- Cumhuriyet University
RECURRENT GLIOBLASTOMA
Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma
This Phase II clinical trial is an open label, single arm, multicenter study of the combination of intravenously administered SGT-53 and oral temozolomide in patients with confirmed glioblastoma who have proven tumor recurrence…
- Trial name
- NCT02340156
- Testing
- SGT-53, Temozolomide
- Where
- 2 sites in United States, Taiwan
- Volunteers
- 1 people
- Sponsor
- SynerGene Therapeutics, Inc.
Graves' Disease
Genetic Polymorphisms Associated With Cigarette Smoking and Risk of Graves' Disease
Cigarette smoking is a well-recognized risk factor of Graves' disease and, particularly, Graves' ophthalmopathy. Hence, germline polymorphisms of detoxification genes and genes belonging to the major DNA repair/apoptosis pathways…
- Trial name
- NCT00505011
- Volunteers
- 1,998 people, healthy volunteers welcome
- Sponsor
- University of Campinas, Brazil
Progressive Metastatic Malignancies
Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies
This is a Phase 1, open-labeled, non-randomized, multi-center, competitive enrollment and dose-escalation study of ALT-801, the study drug.
- Trial name
- NCT00496860
- Testing
- ALT-801
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- Altor BioScience
Breast Cancer
Duct Endoscopy in Assessing Cellular Atypia in the Breast Duct Fluid of Women With a Genetic Risk for Breast Cancer
RATIONALE: Diagnostic procedures, such as breast duct endoscopy, may improve the ability to detect breast cancer earlier and plan more effective treatment.
- Trial name
- NCT00082979
- Testing
- cytogenetic analysis, proteomic profiling, cytology specimen collection procedure
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Royal Marsden NHS Foundation Trust
HCC, Diabetes
p53 Gene Therapy in Treatment of Diabetes Concurrent With Hepatocellular Carcinoma
An open-labeled phase II study to investigate preliminary efficacy using p53 gene therapy in treatment of diabetes concurrent with hepatocellular carcinoma (HCC).
- Trial name
- NCT02561546
- Testing
- p53 gene therapy, Trans-catheter embolization
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shenzhen SiBiono GeneTech Co.,Ltd
Breast Cancer
Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Currently patients with breast cancer are treated with one of several very similar combinations of drugs.
- Trial name
- NCT00017095
- Testing
- filgrastim, cyclophosphamide, docetaxel
- Where
- 39 sites in Belgium, France and 7 more
- Volunteers
- 1,856 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Rectal Cancer
p53 and Response to Preoperative Radiotherapy for T2 and T3
Background: Meta-analyses of large randomized trials proved the superiority of preoperative short course radiation and surgery, as compared with surgery alone.
- Trial name
- PART1 (NCT02140723)
- Testing
- preoperative short course radiation
- Where
- Austria
- Volunteers
- 60 people
- Sponsor
- Medical University of Vienna
HCC - Hepatocellular Carcinoma, TP53 Gene Mutation
A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma
This study aims to evaluate the effectiveness and safety of a combination therapy with Fuxinqibai monoclonal antibody, Tislelizumab, and Lenvatinib in patients with advanced, unresectable TP53-mutated hepatocellular carcinoma…
- Conditions
- HCC - Hepatocellular Carcinoma, TP53 Gene Mutation, Unresectable, Resistant Cancer
- Trial name
- NCT07535840
- Testing
- Firsekibart + Tislelizumab + Lenvatinib
- Volunteers
- 25 people
- Sponsor
- Tongji Hospital
Lip and Oral Cavity Cancer, Oropharyngeal Cancer
Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx
This phase I/II trial is studying the side effects and best dose of gene therapy and to see how well it works in preventing cancer in patients with premalignant carcinoma of the oral cavity or pharynx.
- Conditions
- Lip and Oral Cavity Cancer, Oropharyngeal Cancer, Stage 0 Lip and Oral Cavity Cancer, Stage 0 Oropharyngeal Cancer
- Trial name
- NCT00064103
- Testing
- Ad5CMV-p53 gene, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- National Cancer Institute (NCI)
Metformin, Prediabetes
Metformin and Molecular Aging in Prediabetes
The incidence and prevalence of type 2 diabetes mellitus (T2DM) are increasing globally. The global prevalence of diabetes has nearly doubled since 1980, rising from 4.7% to 8.5% in the adult population.
- Trial name
- NCT07302932
- Testing
- Metformin treatment, Analyzed by qPCR for T/S ratio.
- Where
- India
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Diabetes Foundation, India
Acute Myeloid Leukemia, Myelodysplastic Neoplasm
Oral-ATO for TP53-mutated Myeloid Malignancies
This is an open-label, phase 2 study of oral arsenic trioxide (Arsenol ®) in combination with ascorbic acid and investigator choice of low-intensity therapy in patients with previously untreated or relapse/refractory TP53-mutated…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Neoplasm, Chronic Myelomonocytic Leukemia, TP53 Gene Mutation
- Trial name
- NCT06778187
- Testing
- Oral arsenic trioxide
- Where
- Hong Kong
- Volunteers
- 30 people
- Sponsor
- The University of Hong Kong
Acute Myocardial Infarction
A Comparison of p53-induced Genes Activation in Patients With and Without Acute Myocardial Infarction
The purpose of this study is to compare p53-induced genes activation as possible markers differentiating between patients presenting with acute myocardial infarction and controls.
- Trial name
- NCT01191879
- Testing
- Blood test
- Where
- Israel
- Volunteers
- 79 people
- Sponsor
- Meir Medical Center
Liver Cancer
Gene Therapy in Treating Patients With Cancer of The Liver
Phase I trial to study the effectiveness of gene therapy with the p53 gene in treating patients who have cancer of the liver that cannot be surgically removed.
- Trial name
- NCT00003147
- Testing
- Ad5CMV-p53 gene
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)